At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
Orforglipron +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Drug-Drug Interaction, Single-arm, Open-label Study to Assess the Effect of Quinidine on the Pharmacokinetics of Orforglipron in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating Orforglipron, Midazolam, and 1 other intervention for Healthy. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effect of quinidine on the levels of orforglipron in the blood stream and how long it takes the body to eliminate it, when administered orally in healthy participants. The study will last up to approximately 8 weeks including screening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20252026
First PostedNov 2024
Enrollment StartDec 2024
Primary CompletionFeb 2025
TodayJul 2026
First PostedNov 26, 2024
Enrollment StartDec 6, 2024
Primary CompletionFeb 5, 2025
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 1.6 years ago
Interventions
Orforgliprondrug
Administered orally
Midazolamdrug
Administered orally
Quinidinedrug
Administered orally